Literature DB >> 17669572

The impact of ziprasidone in combination with sertraline on visually-evoked event-related potentials in depressed patients with psychotic features.

O Moeller1, S Evers, J Deckert, B T Baune, U Dannlowski, D H Nguyen, V Arolt, G Hetzel.   

Abstract

BACKGROUND: The use of atypical antipsychotics in major depression complicated by psychotic features has not been extensively investigated. Event-related potentials (ERP) have been reported to be impaired in depressed patients, probably due to serotonergic hypofunction. The objective of this study was to examine the effects of a combination therapy with ziprasidone and sertraline on ERP in major depression with psychotic features.
METHODS: 19 patients with major depression with psychotic features were treated with ziprasidone and sertraline. Before and after four weeks of treatment, visually-evoked ERP (P3 -- oddball paradigm) were investigated.
RESULTS: While a significant clinical improvement assessed with the Brief Psychiatric Rating Scale and Hamilton Depression Rating Scale was noted, no significant changes in weight, basal prolactin values and scores on the Extrapyramidal Symptoms Scale were observed. A significant prolongation (p = 0.041) of the QTc-interval between baseline and endpoint showed no clinical symptoms. Combination treatment with ziprasidone and sertraline over 4 weeks was associated with a significant decrease (p = 0.033) of P3 latencies from baseline to week 4. After a four week treatment, significantly (p = 0.008) fewer patients showed pathologically P3 latencies (>450 ms) than at baseline. DISCUSSION: Our data, showing that ziprasidone in combination with sertraline lead to a decrease of prolonged P3 latencies, are in line with previous studies showing a decrease of prolonged P3 latencies by antidepressant treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17669572     DOI: 10.1016/j.pnpbp.2007.06.021

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  2 in total

1.  The lack of effect of ziprasidone on platelet serotonin concentration in schizophrenic patients.

Authors:  Marina Sagud; Matea Nikolac; Alma Mihaljevic-Peles; Gordana Nedic; Bjanka Vuksan Cusa; Maja Mustapic; Miro Jakovljevic; Dorotea Muck-Seler; Nela Pivac
Journal:  Psychopharmacology (Berl)       Date:  2011-10-12       Impact factor: 4.530

2.  Evidence review and clinical guidance for the use of ziprasidone in Canada.

Authors:  David M Gardner; Andrea L Murphy; Stan Kutcher; Serge Beaulieu; Carlo Carandang; Alain Labelle; Pierre Lalonde; Ashok Malla; Heather Milliken; Claire O'Donovan; Ayal Schaffer; Jorge Soni; Valerie H Taylor; Richard Williams
Journal:  Ann Gen Psychiatry       Date:  2013-01-24       Impact factor: 3.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.